Codexis, Inc. CDXS
Major Chemicals · IPO 2010 · data as of November 13, 2026
Codexis, Inc. (CDXS) is a industrial company listed in the US with a market value of about $127M. In the twelve months to September 30, 2026 it had revenue of $88M and net income of -$19M, a net margin of -21.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 0% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Codexis
Codexis is listed in the US and classified in major chemicals, IPO year 2010. Revenue went from $35M in 2014 to $70M in 2025, growth of about 6.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 74% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M |
| Net income | -$19M | -$44M | -$65M | -$76M | -$34M | -$21M | -$24M | -$12M | -$11M | -$23M | -$9M |
| Free cash flow | -$12M | -$24M | -$54M | -$57M | $3M | -$28M | -$20M | -$16M | -$17M | -$10M | -$3M |
| EPS (diluted) | $-0.19 | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | $-0.21 | $-0.50 | $-0.21 |
| Net margin | -21.8% | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% | -17.4% | -17.9% | -46.0% | -17.5% |
| ROIC | — | -26.7% | -36.4% | -52.4% | -14.6% | -8.5% | -9.7% | -7.5% | -20.0% | -73.0% | -44.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $6.14, 430% above the current price; targets range from $2.00 to $11.00; the consensus rating is “Buy”; expected EPS is $-0.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Codexis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Codexis pay a dividend?
Not currently.
Is Codexis a good stock to buy?
We do not give buy or sell advice. Codexis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.